Radioimmunoassay of tissue steroids in adenocarcinoma of the prostate

J. A. Belis, W. F. Tarry

    Research output: Contribution to journalArticle

    9 Citations (Scopus)

    Abstract

    Tissue steroid levels in 48 needle-biopsy samples of adenocarcinomas of the prostate were quantified by radioimmunoassay (RIA). Tissue levels of dihydrotestosterone (DHT), estradiol-17β, and estrone were correlated with tumor stage, histologic grade, and patients response to endocrine therapy. All patients with well-differentiated carcinomas of the prostate had tissue DHT content greater than 2.0 ng/g while 35% of patients with moderately differentiated or poorly differentiated tumors had tissue DHT content less than 2.0 ng/g. DHT content appeared to be unrelated to tumor stage. Estradiol and estrone content correlated well with tumor grade but not with tumor stage. Thirteen patients with DHT content greater than 2.0 ng/g initially had an objective and/or subjective response to endocrine therapy. Four patients with tissue DHT levels below 2.0 ng/g had no response to hormonal therapy. Quantitation of tissue DHT content by RIA is a promising method for predicting initial response to hormonal therapy in adenocarcinoma of the prostate.

    Original languageEnglish (US)
    Pages (from-to)2416-2419
    Number of pages4
    JournalCancer
    Volume48
    Issue number11
    StatePublished - 1981

    Fingerprint

    Dihydrotestosterone
    Radioimmunoassay
    Prostate
    Adenocarcinoma
    Steroids
    Estrone
    Neoplasms
    Estradiol
    Needle Biopsy
    Therapeutics
    Carcinoma

    ASJC Scopus subject areas

    • Cancer Research
    • Oncology

    Cite this

    Belis, J. A., & Tarry, W. F. (1981). Radioimmunoassay of tissue steroids in adenocarcinoma of the prostate. Cancer, 48(11), 2416-2419.

    Radioimmunoassay of tissue steroids in adenocarcinoma of the prostate. / Belis, J. A.; Tarry, W. F.

    In: Cancer, Vol. 48, No. 11, 1981, p. 2416-2419.

    Research output: Contribution to journalArticle

    Belis, JA & Tarry, WF 1981, 'Radioimmunoassay of tissue steroids in adenocarcinoma of the prostate', Cancer, vol. 48, no. 11, pp. 2416-2419.
    Belis, J. A. ; Tarry, W. F. / Radioimmunoassay of tissue steroids in adenocarcinoma of the prostate. In: Cancer. 1981 ; Vol. 48, No. 11. pp. 2416-2419.
    @article{8082e9e32af941d0a1f0cc4e81bc8e24,
    title = "Radioimmunoassay of tissue steroids in adenocarcinoma of the prostate",
    abstract = "Tissue steroid levels in 48 needle-biopsy samples of adenocarcinomas of the prostate were quantified by radioimmunoassay (RIA). Tissue levels of dihydrotestosterone (DHT), estradiol-17β, and estrone were correlated with tumor stage, histologic grade, and patients response to endocrine therapy. All patients with well-differentiated carcinomas of the prostate had tissue DHT content greater than 2.0 ng/g while 35{\%} of patients with moderately differentiated or poorly differentiated tumors had tissue DHT content less than 2.0 ng/g. DHT content appeared to be unrelated to tumor stage. Estradiol and estrone content correlated well with tumor grade but not with tumor stage. Thirteen patients with DHT content greater than 2.0 ng/g initially had an objective and/or subjective response to endocrine therapy. Four patients with tissue DHT levels below 2.0 ng/g had no response to hormonal therapy. Quantitation of tissue DHT content by RIA is a promising method for predicting initial response to hormonal therapy in adenocarcinoma of the prostate.",
    author = "Belis, {J. A.} and Tarry, {W. F.}",
    year = "1981",
    language = "English (US)",
    volume = "48",
    pages = "2416--2419",
    journal = "Cancer",
    issn = "0008-543X",
    publisher = "John Wiley and Sons Inc.",
    number = "11",

    }

    TY - JOUR

    T1 - Radioimmunoassay of tissue steroids in adenocarcinoma of the prostate

    AU - Belis, J. A.

    AU - Tarry, W. F.

    PY - 1981

    Y1 - 1981

    N2 - Tissue steroid levels in 48 needle-biopsy samples of adenocarcinomas of the prostate were quantified by radioimmunoassay (RIA). Tissue levels of dihydrotestosterone (DHT), estradiol-17β, and estrone were correlated with tumor stage, histologic grade, and patients response to endocrine therapy. All patients with well-differentiated carcinomas of the prostate had tissue DHT content greater than 2.0 ng/g while 35% of patients with moderately differentiated or poorly differentiated tumors had tissue DHT content less than 2.0 ng/g. DHT content appeared to be unrelated to tumor stage. Estradiol and estrone content correlated well with tumor grade but not with tumor stage. Thirteen patients with DHT content greater than 2.0 ng/g initially had an objective and/or subjective response to endocrine therapy. Four patients with tissue DHT levels below 2.0 ng/g had no response to hormonal therapy. Quantitation of tissue DHT content by RIA is a promising method for predicting initial response to hormonal therapy in adenocarcinoma of the prostate.

    AB - Tissue steroid levels in 48 needle-biopsy samples of adenocarcinomas of the prostate were quantified by radioimmunoassay (RIA). Tissue levels of dihydrotestosterone (DHT), estradiol-17β, and estrone were correlated with tumor stage, histologic grade, and patients response to endocrine therapy. All patients with well-differentiated carcinomas of the prostate had tissue DHT content greater than 2.0 ng/g while 35% of patients with moderately differentiated or poorly differentiated tumors had tissue DHT content less than 2.0 ng/g. DHT content appeared to be unrelated to tumor stage. Estradiol and estrone content correlated well with tumor grade but not with tumor stage. Thirteen patients with DHT content greater than 2.0 ng/g initially had an objective and/or subjective response to endocrine therapy. Four patients with tissue DHT levels below 2.0 ng/g had no response to hormonal therapy. Quantitation of tissue DHT content by RIA is a promising method for predicting initial response to hormonal therapy in adenocarcinoma of the prostate.

    UR - http://www.scopus.com/inward/record.url?scp=0019864702&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=0019864702&partnerID=8YFLogxK

    M3 - Article

    C2 - 7296491

    AN - SCOPUS:0019864702

    VL - 48

    SP - 2416

    EP - 2419

    JO - Cancer

    JF - Cancer

    SN - 0008-543X

    IS - 11

    ER -